Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn’s disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS study [PDF]
Therapeutic Advances in GastroenterologyBackground: Anti-tumor necrosis factor (TNF) agents are now accepted as the first-line medical treatment for stricturing Crohn’s disease (CD). However, data are lacking about the effectiveness of advanced therapies after anti-TNF failure.
Guillaume Le Cosquer +4 more
doaj +2 more sources
Immunologic Parameters for Disease Activity in Rheumatoid Arthritis [PDF]
Archives of Razi Institute, 2021 This study aimed to determine the correlation of disease activity of rheumatoid arthritis (RA) with Th17/regulatory T cell (Treg) and Forkhead box protein 3 (Foxp3) cells ratio in patients under therapy with anti-tumor necrosis factor (TNF)-α.
E Riyadh Mohsen +2 more
doaj +1 more source
Therapeutic drug monitoring for biological medications in inflammatory bowel disease
The Saudi Journal of Gastroenterology, 2022 Therapeutic drug monitoring (TDM) is the measurement of serum drug concentrations and anti-drug-antibodies (ADA) for biologic therapies used to treat inflammatory bowel disease (IBD). The aim of this article is to review the current literature concerning
Rachel C Cogan +2 more
doaj +1 more source
Journal of Investigative Surgery, 2022 Background Massive or repeated intestinal resections for Crohn’s disease (CD) could lead to disabling consequences. The present study aimed to assess the effect of preoperative anti-TNF therapy on the length of resected bowel and identify risk factors ...
Yuhua Huang +4 more
doaj +1 more source
Pityriasis rubra pilaris developing after COVID-19
Turkderm Turkish Archives of Dermatology and Venereology, 2022 Coronavirus disease-2019 (COVID-19) has been associated with multiple skin lesions as well as causing common respiratory symptoms. We presented a case of pityriasis rubra pilaris that developed after COVID-19 infection and treated with anti-tumor ...
Mine Müjde Kuş +6 more
doaj +1 more source
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease [PDF]
Intestinal Research, 2022 Background/Aims We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD).
Anthony Buisson +10 more
doaj +1 more source
THE EVOLUTION OF SPONDYLARTHRITIS – A THERAPEUTIC CHALLENGE [PDF]
Romanian Journal of Rheumatology, 2017 We are presenting the case of a 36 years old male diagnosed at the age of 20 with reactive arthritis and at 27 years with ankylosing spondylitis. During the course of the disease, the patient followed treatment with non-steroidal anti-inflammatory drugs,
Cristina Radu +2 more
doaj +1 more source
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
GMS Ophthalmology Cases, 2023 Objective: To present a case with infliximab-induced retrobulbar optic neuritis.Case description: A 58-year-old woman presented to our clinic with a two-day history of blurred vision in her right eye.
Dündar, Sema +4 more
doaj +1 more source
Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
JGH Open, 2020 Background and Aims Anti‐Tumor Necrosis Factor (TNF)‐induced lupus (ATIL) is a distinct clinical entity, increasingly recognized in patients with inflammatory bowel disease treated with anti‐TNF therapy.
Sherman Picardo +2 more
doaj +1 more source
Indian Journal of Ophthalmology, 2020 Purpose: To evaluate the effectiveness of biologic therapy in a cohort of patients with various types of refractory non-infectious uveitis and scleritis.
Soumen Sadhu +2 more
doaj +1 more source